• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

Jim Mellon Funds Aging Research at University of Oxford


  • Please log in to reply
1 reply to this topic

#1 Engadin

  • Guest
  • 198 posts
  • 580
  • Location:Madrid
  • NO

Posted 18 May 2020 - 05:31 PM


.

 

 

 

 

S O U R C E :   Life Extension Advocacy Foundation

 

 

 

 

 

 

 

oriel-college.jpg

 

 

 

Investment mogul Jim Mellon has donated a record-breaking 1 million British pounds to Oriel College in the United Kingdom, offering a ray of light for aging research.
 
 
Supporting fundamental research on aging
 
In recent years, one of the real dynamos of our community has been British investor and philanthropist Jim Mellon. Jim is perhaps best known for his investment support of promising aging-focused biotech companies through his company Juvenescence, which has invested in rising stars such as Lygenesis, AgeX, and Insilico Medicine.
 
Jim has also been actively involved in the community and is frequently seen attending various aging research conferences, rallying investors to help build the fledgling but steadily growing rejuvenation industry, lobbying government, and supporting basic research on aging.
 
Today’s story is an example of the latter, as Jim has stepped up to support the fundamental aging research happening in the United Kingdom, which has been an important hub for this sort of research. We are happy to learn that Jim has generously donated £1 million for the support of longevity research at Oriel College, which is part of Oxford University. This donation establishes the Mellon Longevity Science Program at Oriel College with the aim of advancing research into health resilience in the elderly.
 
Jim’s donation will directly support the research of Professor Lynne Cox, a George Moody Fellow in Biochemistry at Oriel and a principal investigator within the Department of Biochemistry. The Cox lab is studying the molecular basis of human aging with the goal of reducing age-related morbidity and frailty though improving health resilience. This could include researching therapies for strategies such as boosting the immune systems of older people in order to help them maintain health as well as reducing the effects of sarcopenia and frailty with advancing age to improve quality of life.
 
Jim’s stated reasons for supporting Oriel College are as follows:
 
 
There has never been a more important time to address the frailty of human health. The COVID-19 pandemic has highlighted the huge economic and social costs connected to the lack of immune resilience in our increasingly ageing population and the need for greater scientific research into this area.
 
Boosting immunoresilience among the most vulnerable in society and advancing healthspan are critical to helping more people reach their potential as well as, more urgently, improving our collective resilience in the face of future pandemics. Oxford’s leadership in the field of research and understanding of the ageing process makes it a natural home to advance longevity science and support the growth of the longevity industry, and I am proud to support this work.
 
In addition, the donation will also allow the creation of a DPhil scholarship in Aging and Cell Senescence at Oriel College. The plan is that the first recipient of the DPhil scholarship will join the College for the 2020-21 academic year and will help foster a future generation of aging researchers to join the existing leaders in the field.
 
 
 
Conclusion
 
This donation is a record breaker in the context of aging research at a UK university, making Oriel, and Oxford in general, a real hub for this line of scientific inquiry. Oxford University has long had links to the rejuvenation research community, as it was the scene of a 2012 debate between Dr. Aubrey de Grey and Professor Colin Blakemoor over the desirability of increasing healthy human lifespans, the conclusion of which was somewhat undecided at the time.
 
 
 
 
 
.../...
 
 
 
 
 
 
 
 
 
 
.

 



#2 reason

  • Guardian Reason
  • 1,101 posts
  • 286
  • Location:US

Posted 19 May 2020 - 10:22 AM

Jim Mellon is doing a fair amount to help push the research and medical communities towards the development of therapies to slow and reverse the progression of aging. He is quite vocal in the business community, and is one of the founders of Juvenescence, very much involved in building portions of a longevity-focused biotechnology industry. He wrote a book on that topic as a part of convincing the broader investment community that this is an important new field. He has set up conferences, both for industry and for the broader community, such as the Longevity Forum. Here is an example of another approach, which is to fund institutional research programs to advance the state of the science.

We are delighted to announce that Jim Mellon (1975, PPE), British investor and philanthropist, has gifted £1 million to support and advance the study of Longevity Science at Oxford, and specifically at Oriel. The gift will establish the Mellon Longevity Science Programme at Oriel to help the most vulnerable in society by advancing research into health resilience in ageing populations. The gift is the largest of its kind dedicated to Longevity Science to a UK university, making Oriel and Oxford a focal point for efforts to improve future health resilience by boosting the immunity and healthspan of ageing populations. More specifically, the gift will support the work of Professor Lynne Cox, George Moody Fellow in Biochemistry at Oriel, and a principal investigator in the Department of Biochemistry. Her lab studies the molecular basis of human ageing, with the aim of reducing the morbidity and frailty associated with old age through better health resilience.

"There has never been a more important time to address the frailty of human health. The COVID-19 pandemic has highlighted the huge economic and social costs connected to the lack of immune resilience in our increasingly ageing population and the need for greater scientific research into this area. Boosting immunoresilience among the most vulnerable in society and advancing healthspan are critical to helping more people reach their potential as well as, more urgently, improving our collective resilience in the face of future pandemics. Oxford's leadership in the field of research and understanding of the ageing process makes it a natural home to advance longevity science and support the growth of the longevity industry, and I am proud to support this work."

Link: https://www.oriel.ox...mproving-future


View the full article at FightAging




2 user(s) are reading this topic

0 members, 2 guests, 0 anonymous users